Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptide NA17-A2 antigen (NA17-A2)
- Target
- NA17-A2
- Molecular classification
- Other (Tumor-associated antigen), Peptide antigen presented by HLA-A2
01
Overview
The NA17-A2 antigen is a nonamer peptide (sequence: VLPDVFIRC) encoded by an intron of the N-acetylglucosaminyltransferase V (MGAT5) gene, not typically expressed in normal tissues but found in a subset of melanoma and other tumor cells. It is processed and presented on the surface of HLA-A2-positive tumor cells, making it a target for immunotherapeutic approaches in cancer. The antigen has been used in clinical trials as a component of peptide vaccines and for monitoring tumor antigen-specific CD8+ T cell responses in patients with melanoma. Induction of NA17-A2-specific immune responses has been demonstrated in vaccine studies, and its specificity helps minimize autoimmune risk.
- Other names
- NA17.A2 antigenNA17 peptideNA17NA17 antigen
02
Mechanism of action
Induction of specific cytotoxic T lymphocytes (CD8+ T cells) recognizing NA17-A2 peptide presented on HLA-A2-positive tumor cells, leading to immune-mediated tumor cell killing
03
Biological functions
Immune response stimulation (as a T cell epitope)
04
Disease associations
Cancer (primarily melanoma)
05
Safety considerations
Common safety concerns for peptide cancer vaccines include limited immunogenicity, risk of autoimmunity (theoretical), and immunotherapy-related adverse events (as seen in other T cell–based therapies); specific major safety liabilities for NA17-A2 are not widely reported in the literature
06
Interacting drugs
Peptide-based cancer vaccines
1 more in the full profile.
07
Biomarkers
Detection of NA17-A2-specific T cell responses (e.g., tetramer staining to monitor immune activation in vaccinated patients)
Beyond the preview
Go deeper on Peptide NA17-A2 antigen (NA17-A2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptide NA17-A2 antigen (NA17-A2).